Dr. Rothman is the Medical Director of the BE-LITE Medical Centers located
in Virginia and Gaithersburg, Maryland.

Dr. Rothman, who is Board Certified in Psychiatry,
received his MD degree and his Ph.D. degree in Pharmacology from the University
of Virginia, Charlottesville, Virginia, in 1982. From 1982-1984, Dr. Rothman
was awarded a PRAT Fellowship to conduct postdoctoral research at the National
Institute of Mental Health, Bethesda, MD. From 1984 to 1988 Dr. Rothman served
his Psychiatric Residency at St. Elizabeths Hospital, Washington DC, and later
at the Laboratory of Clinical Science, National Institute of Mental Health,
Bethesda, MD.

Dr. Rothman has published over 320 scientific papers
in peer-reviewed scientific journals and has presented over 390 scientific
abstracts at national and international scientific meetings. Dr. Rothmanıs
published work on appetite suppressants has established him as a leading expert
in this area.

Dr. Rothman has received numerous awards recognizing
his work, including the Joseph Cochin Young Investigator Award awarded
by the Committee on Problems of Drug Dependence, Inc., June 17, 1991; The Scientific
Achievement Award in Biological Sciences for contributions in the field of opioid
pharmacology by the Washington Academy of Sciences, May 18, 1989; and the A. E.
Bennett Award (basic science) by the Society for Biological Psychiatry, May, 1987.

In addition to his extensive experience in the
treatment of obesity, Dr. Rothman also has extensive clinical experience in the
psychopharmacological treatment of psychiatric disorders. Dr. Rothman is a
member of several professional groups, including the American College of
Neuropsychopharmacology, the Society for Neuroscience, the Society of
Biological Psychiatry, the American Society for Pharmacology and Experimental
Therapeutics, and the American Psychiatric Association. Dr. Rothman is licensed
to practice medicine in Maryland, Virginia and the District of Columbia.

Selected Bibliography of Publications
Rothman, RB, Clark, RD, Partilla, JS, Baumann, MH,
(+)-fenfluramine and its major metabolite, (+)-norfenfluramine, are potent
substrates for norepinephrine transporters, J Pharmacol Exp Ther,(2003)
305 1191-9.Rothman, RB, Vu, N, Partilla, JS, Roth, BL, Hufeisen,
SJ, Compton-Toth, BA, Birkes, J, Young, R, Glennon, RA, (2003). In vitro
characterization of ephedrine-related stereoisomers at biogenic amine
transporters and the receptorome reveals selective actions as norepinephrine
transporter substrates, J. Pharmacol. Exp. Ther. 307(1):138-145.

Rothman, R. B., T. Gendron, and P. Hitzig
(1994). Combined use of fenfluramine and phentermine in the treatment of
cocaine addiction: a pilot case series. J. Subst. Abuse.

Rothman, RB, Anorexogen-related cardiac valvulopathy, Ann Intern Med,
(2002) 136 779.

Rothman, RB, Baumann, MH, Serotonin releasing agents. Neurochemical, therapeutic and adverse effects,
Pharmacol Biochem Behav,(2002) 71 825-36.

Rothman, RB, Blough, BE, Baumann, MH, Appetite
suppressants as agonist substitution therapies for stimulant dependence, Ann N
Y Acad Sci,(2002) 9651 09-26.

Rothman, RB, The age-adjusted mortality rate from primary pulmonary hypertension,
in age range 20 to 54 years, did not increase during the years of peak Phen/Fen use,
Chest,(2000) 118 1516-1517.

Baumann, M. H., M. A. Ayestas, C. M. Dersch, A. Brockington, K. C. Rice, and
R. B. Rothman (2000). Effects of phentermine and fenfluramine on extracellular
dopamine and serotonin in rat nucleus accumbens: therapeutic implications.
Synapse, 36:102-113.

Rothman, RB, Baumann, MH, Savage, JE, Rauser, L,
McBride, A, Hufisein, S, Roth, BL, Evidence for possible involvement of 5-HT_2B
receptors in the cardiac valvulopathy associated with fenfluramine and other
serotonergic medications, Circulation,(2000) 102 2836-2841.

Rothman, R. B., J. B. Redmon, S. K. Raatz, C. A.
Kwong, J. E. Swanson, and J. P. Bantle (2000). Chronic treatment with the
phentermine combined with fenfluramine lowers plasma serotonin.
Am. J. Cardiol., 85(7):913-915.

Rothman, R. B., M. A. Ayestas, C. M. Dersch, and M. H.
Baumann (1999). Aminorex, fenfluramine, and chlorphentermine are serotonin
transporter substrates: implications for primary pulmonary
Circulation, 100:869-875.

Rothman, R. B. (1999). Does phentermine inhibit monoamine oxidase?
The Lancet, 353(9161):1362-1363.

Rothman, R. B. (1999). Is phentermine an inhibitor of monoamine oxidase? A critical
appraisal. Synapse, 32:141-145.

Wojnicki, F. H. E., R. B. Rothman, K. C. Rice, and J.
R. Glowa (1999). Effects of phentermine on responding maintained under multiple
fixed-ratio schedules of food and cocaine presentation in the rhesus monkey.
J. Pharmacol. Exp. Ther., 288(2):550-560.

Rothman R. B., G. I. Elmer, T. S. Shippenberg, W. Rea, and M. H. Baumann
(1998).Phentermine and fenfluramine: preclinical studies in animal models of
cocaine addiction. In: The Neurochemistry of Drugs of Abuse - Cocaine, Ibogaine,
and Substituted Amphetamines, Syed F. Ali (ed), Ann. N.Y. Acad. Sci., 844:59-74.

Rea, W. P., R. B. Rothman, and T. S. Shippenberg (1998).Evaluation of the
conditioned reinforcing effects of phentermine and fenfluramine in the
rat:concordance with clinical studies.Synapse, 30(1):107-111.

Glowa, J. R., K. C. Rice, D. Matecka, and R. B. Rothman (1997).
Phentermine/fenfluramine decreases cocaine self-administration in rhesus
monkeys.NeuroReport, 8:1347-1351.

Rothman, R. B. (1997).Brain serotonin neurotoxicity and fenfluramine and
dexfenfluramine. J. Am. Med. Assoc., 278(24):2142.

Shoaib, M., M. H. aumann, R. B. Rothman, S. R. Goldberg, and C. W. Schindler
(1997).Behavioural and neurochemical characteristics of phentermine and
fenfluramine administered separately and as a mixture in rats.
Psychopharmacol. 131:296-306.

Rothman, R. B. (1996).Smoking cessation in a patient being treated with
fenfluramine plus phentermine for simple obesity.
J. Clin. Psychiatry, 57(2):92-93.

Brauer, L. H., C. E. Johanson, C. R. Schuster, R. B. Rothman, and H. de Wit
(1996).Evaluation of phentermine and fenfluramine, alone and in combination, in
normal, healthy volunteers.Neuropsychopharmacology, 14(4):233-241.

Rothman, R. B. (1996). Treatment of a four year old boy with ADHD with the dopamine
releaser phentermine. J. Clin. Psychiatry, 57(7):308-309.

Rothman, R. B., M. Ayestas, and M. H. Baumann (1996).Phentermine pretreatment
antagonizes the cocaine-induced rise in mesolimbic dopamine.NeuroReport, 9:7-9.

Baumann, Michael H., C. R. Schuster, and R. B. Rothman (1996). Effects of
phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse
brain. Alcohol Depend., 41:71-74.